Tesofensine Side Effects

Reported Tesofensine side effects

Tesofensine's side effect profile reflects its monoamine-enhancing mechanism. Most effects are predictable extensions of NE, DA, and 5-HT elevation. The cardiovascular profile is the dominant clinical concern and the primary reason regulators have not approved the drug. Cardiovascular Effects (Most Important): Heart rate elevation: the signature CV effect. At 1.0 mg daily, heart rate increased ~7.5 bpm vs placebo in the pivotal trial. At 0.5 mg the effect is smaller but measurable. Mechanism is peripheral noradrenergic reuptake inhibition producing sympathetic activation. Blood pressure: systolic and diastolic trends upward, though in TIPO-1 the changes did not reach statistical significance at most timepoints. Orthostatic blood pressure showed larger changes than supine. Palpitations: reported by subset of patients, particularly at 1.0 mg dose. Risk context: sustained HR elevation is associated with increased CV event risk in epidemiologic studies; the magnitude-of-risk translation for tesofensine specifically is unknown without a cardiovascular outcomes trial. The sibutramine SCOUT trial (sibutramine vs placebo in high-CV-risk obese patients) showed 16% increased composite CV event rate with sibutramine — tesofensine's monoamine profile is similar enough that a comparable signal is plausible but unconfirmed. Neuropsychiatric Effects: Insomnia: common. Monoamine reuptake inhibition produces stimulant-like wakefulness; the long half-life means even morning dosing produces residual stimulant activity at bedtime. Reported in 20-30% of patients at 1.0 mg. Anxiety: related to NE elevation; commonly reported particularly in susceptible individuals. Dry mouth: xerostomia from sympathetic activation of salivary glands; very common. Constipation: anticholinergic-like effect from sympathetic tone changes. Dizziness: orthostatic effects; reported especially early in treatment. Irritability, restlessness: mild stimulant-type subjective effects. Mood changes: generally positive at modest doses (mild antidepressant-like), but occasional dysphoria or anxiety, particularly in patients with bipolar tendencies or existing anxiety disorders. Monoamine-Specific Risks: Serotonin syndrome: risk is elevated when tesofensine is combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, triptans, MDMA, certain recreational substances). Clinical features include autonomic instability, neuromuscular changes, altered mental status. Given tesofensine's long half-life, risk persists for weeks after discontinuation. Hypertensive crisis: possible with concurrent MAOI use (absolute contraindication) or sympathomimetic medications. Arrhythmia: tachyarrhythmias reported in susceptible patients, particularly with pre-existing atrial fibrillation. Metabolic Effects: Appetite suppression: the intended effect, but can become problematic if resulting in inadequate nutrition. Weight loss: can be substantial; patients should monitor for lean mass loss without adequate protein intake and resistance training. Lipid profile: generally improves with weight loss (HDL up, triglycerides down). Glucose: typically improves with weight loss; tesofensine itself does not appear to have direct insulin-sensitizing effects independent of weight reduction. Other Effects: Urinary retention: less common; sympathetic effects on bladder neck. Sweating changes: occasional reports of either hyperhidrosis or hypohidrosis. Gastrointestinal: nausea, dyspepsia, abdominal discomfort in minority of patients (much less than GLP-1 agonists). Discontinuation Considerations: Given the 9-day half-life, abrupt discontinuation produces a gradual decline in effect over 4-6 weeks rather than acute withdrawal. No classic discontinuation syndrome has been characterized, but: Rebound appetite and weight regain occur as plasma levels decline Any CV benefit from reduced tachycardia is itself gradual Drug-drug interaction considerations (serotonin syndrome risk with new serotonergic agents) persist for weeks post-discontinuation Monitoring Requirements:** Appropriate use of tesofensine requires: Baseline ECG, blood pressure, heart rate Cardiovascular risk assessment (Framingham or similar) Psychiatric history (contraindicated in bipolar, with caution in anxiety disorders) Periodic monitoring of heart rate, blood pressure during use Consideration of holter monitoring if symptomatic palpitations develop Regular weight, lean mass assessment Nutritional adequacy (given appetite suppression)

When to continue, reduce, or stop Tesofensine

Tesofensine contraindications

Absolute Contraindications (Do Not Use): Concurrent MAOI use (within 14 days — longer for transdermal selegiline): risk of hypertensive crisis, serotonin syndrome Known hypersensitivity to tesofensine or any formulation component Active cardiovascular disease: recent MI, unstable angina, uncontrolled arrhythmia, decompensated heart failure Uncontrolled hypertension (BP persistently >160/100) Pheochromocytoma: sympathetic activation contraindicated Severe hepatic impairment (Child-Pugh C) End-stage renal disease Pregnancy: no safety data; monoamine reuptake inhibitors as a class have concerning signals Active substance use disorder with stimulants (cocaine, methamphetamine): additive CV risk, potential for misuse Concurrent use of sibutramine (where still available) or other triple/dual monoamine reuptake inhibitors Relative Contraindications (Use with Significant Caution): Controlled hypertension: baseline BP at upper end of normal; requires close monitoring Mild-moderate heart failure: case-by-case Arrhythmia history (even if currently stable) Psychiatric conditions: Bipolar disorder (risk of mania induction) Generalized anxiety disorder (risk of exacerbation) History of psychosis Concurrent SSRI/SNRI use: serotonin syndrome risk; case-by-case with low doses and close monitoring Elderly (>65): lower starting doses, more gradual titration, enhanced monitoring Hepatic impairment (Child-Pugh B): dose reduction; close monitoring Renal impairment (moderate to severe): dose reduction History of seizures: monoamine enhancement may lower seizure threshold Narrow-angle glaucoma: sympathetic activation may precipitate acute angle-closure Prostatic hyperplasia with urinary retention: sympathetic effects may worsen Drug-Specific Interaction Contraindications: Absolute Avoid: MAOIs (phenelzine, tranylcypromine, selegiline at AD doses, isocarboxazid, moclobemide) Linezolid (reversible MAOI activity) IV methylene blue (MAOI-A activity) Sibutramine, other triple/dual monoamine reuptake inhibitors Cocaine, amphetamine (recreational) Avoid or Extreme Caution: Other serotonergic agents: SSRIs, SNRIs, tricyclic antidepressants, trazodone, tramadol, meperidine, fentanyl, dextromethorphan, St. John's Wort Triptans (sumatriptan etc.) Lithium MDMA (recreational) Caution with Dose Adjustment: CYP3A4 strong inhibitors: ketoconazole, itraconazole, clarithromycin, ritonavir — reduce tesofensine dose CYP3A4 strong inducers: rifampin, phenytoin, carbamazepine, St. John's Wort — may reduce tesofensine efficacy Beta-blockers: clinically useful combination (reduces HR elevation) but monitor for bradycardia at higher doses Thyroid hormones: may compound CV effects at supraphysiologic doses Other weight loss agents: redundancy and additive risk Special Populations and Situations: Pre- and Peri-operative: Discontinue tesofensine at least 2 weeks before elective surgery due to: CV effects (intraoperative hemodynamic concerns) Anesthetic interactions (particularly with halothane, though rarely used modernly) Serotonergic interactions with analgesics (especially meperidine, fentanyl, tramadol) Given 9-day half-life, "2 weeks" is actually shorter than ideal; ≥4 weeks is more complete but often impractical Alcohol: Not absolute contraindication but: Alcohol amplifies sedative effects minimally but amplifies hepatic CYP3A4 burden Worsens sleep disruption from tesofensine Adds CV stress Recommendation: minimize or eliminate alcohol during treatment Caffeine: Not contraindication but: Additive cardiac stimulant effect Worse sleep compounding Recommendation: limit to moderate caffeine (≤200 mg/day) during tesofensine use Concurrent Conditions Requiring Extra Monitoring: Diabetes: tesofensine weight loss improves glycemic control — monitor for hypoglycemia in insulin-treated patients Thyroid disorders: can compound CV effects COPD: caution with sympathetic effects on cardiac rhythm Seizure disorder: seizure threshold lowered ADHD on medication: stimulant redundancy Depression on medication: serotonergic interaction risk Anxiety disorder: may worsen Contraindicated Populations by Age: Pediatric (<12): not studied Adolescent (12-17): studied in Prader-Willi only; general use not indicated Adult (18-65): primary population Elderly (>65): use with caution, lower starting dose Very elderly (>75): generally avoid unless specific circumstances justify Discontinuation Criteria: Immediate discontinuation indicated if: New chest pain, especially with activity Palpitations with syncope or near-syncope Severe hypertension (>180/120 on any reading) Arrhythmia on ECG Signs of serotonin syndrome New or worsening psychiatric symptoms (mania, psychosis, severe anxiety) Pregnancy confirmed Preparation for surgery (2+ weeks before) Starting MAOI Significant weight loss to below healthy BMI Warning Signs Requiring Medical Consultation: Gradual heart rate increase (>10 bpm over baseline) Gradual blood pressure increase (>10 mmHg systolic) Worsening sleep Mood changes New medication combinations Sudden significant weight change (too fast or stalling) Any symptoms concerning for cardiovascular, serotonergic, or psychiatric effects Overdose: Tesofensine overdose presents with: Tachycardia, hypertension Agitation, tremor Potential for serotonin syndrome signs Seizures in severe overdose Arrhythmia risk No specific antidote. Supportive care: ICU monitoring for CV effects Benzodiazepines for agitation/serotonin features Cooling for hyperthermia Cyproheptadine historically for serotonin syndrome (evidence limited) Activated charcoal within 1-2 hours if ingestion recent and airway protected Given 9-day half-life, elimination is prolonged — prepare for extended supportive care

Why vendor quality drives Tesofensine side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Tesofensine side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .